




- (51) International Patent Classification:
C07K 16/28 (2006.01) *A61P 35/02* (2006.01)
A61K 39/395 (2006.01)
- (21) International Application Number:
PCT/US2017/042982
- (22) International Filing Date:
20 July 2017 (20.07.2017)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/364,811 20 July 2016 (20.07.2016) US
- (71) Applicant: JANSSEN PHARMACEUTICA NV
[BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventor: and
- (71) Applicant: ATTAR, Ricardo [US/US]; 1400 McKean Road, Spring House, Pennsylvania 19477 (US).
- (72) Inventors: CHIN, Diana; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). EDAVETTAL, Suzanne; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). GAUDET, Francois; 3210 Merryfield Row, La Jolla, 92121 (UA). LI, Yingzhe; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). LUISTRO, Leopoldo; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). MAJEWSKI, Nathan; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). MEN-DONCA, Mark; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). PILLARISETTI, Kondandaram; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). TEPLYAKOV, Alexey; 1400 McKean Road, Spring House, Pennsylvania 19477 (US). TORNETTA, Mark;

(54) Title: ANTI- GPRC5D ANTIBODIES, BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND USES THEREOF

Figure 1



(57) Abstract: Provided herein are antibodies that specifically bind to GPRC5D. Also described are related polynucleotides capable of encoding the provided GPRC5D-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor GPRC5D-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with GPRC5D-expressing cancer and thus may be amenable to treatment with a GPRC5D-specific anti-cancer therapeutic, such as the multispecific antibodies against GPRC5D and CD3 described herein.

1400 McKean Road, Spring House, Pennsylvania 19477
(US).

(74) **Agent:** SHIRTZ, Joseph F. et al.; JOHNSON & JOHNSON, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*